Seitenanfang

News & Events

05.11.2017 | Marker Test Diagnostics Announces Plan to Release a Liquid Formulation of it Game-Changing Drug Testing Marker

PHOENIX, ARIZONA April 25, 2017 – Marker Test Diagnostics, an international supplier to the drug testing industry, announced today that it plans to release a liquid formulation of UR Code™, its revolutionary drug testing marker. The UR Code urine marker has been available in a soft gel capsule the United States for the past two years. Previously available only outside of the United States, UR Code is an oral marker developed by Marker Test Diagnostics that essentially builds a substance “bar-code” in the donor’s urine and eliminates the need to supervise urine collection.

The U.S. launch for the liquid based UR Code arrives on the heels of a recently completed study within the criminal justice market in the State of Florida, with plans for submission for scientific publication for use and distribution in the US Criminal Justice Markets.

“Over the past two years we have been in constant contact with our customers and end-users and have taken great care to listen to their preferences regarding the use of our soft gel capsule versus an easy to use liquid product,” said Kim Christensen, Chief Executive Office of Marker Test. “The introduction of this new oral application provides strong benefits for both the urine donor in the form of a quick and easy to use application, and the company with the product showing faster absorption rates and earlier detectable levels in the urine.”

The new liquid UR Code formulation, provides a more accurate, secure and cost-effective answer to common drug testing challenges by:
Inhibiting manipulations
Eliminating false negative results
Ensuring sample integrity
Protecting the privacy of the test subject

Christensen will discussing the U.S. market release of the new UR Code product during the Drug and Alcohol Testing Industry Association Conference (booth # 104), May 15-18 2017 at the Rosen Shingle Creek Resort in Orlando, Florida,

About Marker Test Diagnostics

Founded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative oral marker for the drug testing market. Marker Test Diagnostics has and continues to conduct relevant market studies in the field of addiction, criminal justice (corrections, probation, parole, and pre-trial), pain management and sports. For more information about Marker Test Diagnostics, visit www.markertest.com.

01.31.2017 | Marker Test Diagnostics Enters Into Partnership with Atlantic Biotech Labs to Distribute UR Code™ Product

Atlantic Biotech to Provide Drug Testing Marker for Criminal Justice Markets in Florida and Tennessee.

“The partnership with Atlantic Biotech provides for a very unique opportunity for both companies, beginning with the criminal justice markets in Florida and Tennessee,” said Marker Test Chief Executive Officer Kim Christensen. SCOTTDALE, AZ (PRWEB) JANUARY 29, 2017

SCOTTSDALE - January 28, 2017 – Marker Test Diagnostics, Inc., a leading international supplier to the drug testing industry, has entered into an exclusive agreement with Atlantic Biotech Labs of Pompano Beach FL, to distribute its UR Code™ urine marker product.

UR Code is a urine marker that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection. In the form of a soft gel capsule, UR Code is the only patented test worldwide that can analytically detect sample substitution, dilution or adulteration, resulting in unparalleled accuracy and reliability. This superior level of accuracy eliminates up to 30% of the tests that are deliberately falsified in urine drug testing.

This agreement provides Atlantic Biotech with a distinct competitive advantage by delivering improved confirmation testing results to the criminal justice markets (corrections, probation, parole, and drug courts) in the states of Florida and Tennessee. With drug use on the rise and an out of control opioid epidemic nationally, the UR Code product and Atlantic Biotech labs can have a major impact in assisting the criminal justice markets with the latest innovative tools to better manage the clients they serve.

“The partnership with Atlantic Biotech provides for a very unique opportunity for both companies, beginning with the criminal justice markets in Florida and Tennessee,” said Marker Test Chief Executive Officer Kim Christensen. “Together, we believe the specificity of the product will allow Atlantic Biotech Labs to expand their technical operations and expertise in the corrections, probation, parole, and drug court markets by providing the latest technology with enhanced and accurate results reporting to the market decision makers.”

Representatives from both companies are on-site at the AXIS (Addiction eXecutives Industry Summit) in Naples, FL from January 28 to February 1 (booth 26) at the Naples Grand Beach Resort, and at DATIA (Drug and Alcohol Industry Association) conference May 16 -18, in Orlando, FL.

About Atlantic Biotech, LLC
Founded in 2013, Atlantic Biotech, a national provider of drug confirmation testing services utilizes the latest LC/MS/MS technology available today to provide accurate and timely (24 hour) qualitative and quantitative toxicology results. As legal and compliance pressures continue to evolve in the face of today’s toxicology industry, Atlantic Biotech is unsurpassed and leads the industry in compliance. Atlantic Biotech delivers customizable panel solutions along with stringent control, and unparalleled customer service for a wide range of toxicology markets. As a company, a key emphasis lies with being a partner in patient health by working with physicians and facilities more like a family than a large corporation. Atlantic Biotech is taking a leadership role to address the evolving and pressing concerns with “observed” urine collection by ensuring that samples belong to the correct patient and no one else. Atlantic Biotech knows each and every time “lives are on the line.”

For more information about Atlantic Biotech, visit http://www.atlanticbiotech.com.

07.29.2015 | Marker Test Diagnostics Secures Second Agreement to Distribute UR Code™ Product


PSO Laboratory, LLC to Enhance Patient Care by Providing Drug Testing Marker in Michigan
July 28, 2015 08:00 AM Eastern Daylight Time

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Marker Test Diagnostics, Inc., a leading international supplier to the drug testing industry, has secured its second agreement to distribute its UR Code™ urine marker product in the U.S. with PSO Laboratory, a leading provider of drug confirmation testing and toxicology services in Michigan.

“We are very proud to partner with PSO labs as an exclusive sole source distribution partner for the state of Michigan”

UR Code is a urine marker that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection. In the form of a soft gel capsule, UR Code is the only patented test worldwide that can analytically detect sample substitution, dilution or adulteration, resulting in unparalleled accuracy and reliability. This superior level of accuracy eliminates up to 30% of the tests that are deliberately falsified in urine drug testing.

The agreement provides PSO Labs with an exclusive and distinct competitive advantage to improve confirmation in all drug testing market segments in the state of Michigan and a non-exclusive in all other U.S. markets. The companies plan to commercialize the product before the end of the summer.

“We are very proud to partner with PSO labs as an exclusive sole source distribution partner for the state of Michigan,” said Marker Test Chief Executive Officer Kim Christensen. “We believe that together, we can improve the drug testing process in all market segments in Michigan with the focused efforts of PSO Labs. This exclusive three-year agreement gives PSO the opportunity to expand their confirmation statewide. We believe PSO has the expertise and operational excellence to rapidly expand and distribute UR Code as we work together to find ways to reduce the costs of drug testing overall.”

“Marker Test’s unique patient identification system fits perfectly with PSO Laboratory’s focus on patient care, precision toxicology testing and patient responsibility,” stated Michael Barna, M.D., Director of Laboratory Services for PSO Labs. “With the assurance that the sample is correctly associated with the patient, a physician’s ability to provide the patient with an accurate diagnosis and treatment plan is greatly increased. In addition, the often embarrassing and time consuming process of having a staff member monitor the patient during sample collection is eliminated. PSO is excited by this opportunity to provide better patient care by offering the Marker Test program.”

Representatives from Marker Test will be on-site during the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting July 26–30 at the Georgia World Congress Center in Atlanta, Ga (booth 4918). A press conference to discuss the UR Code product; Marker Test’s recent partnerships with PSO and Elithea Sciences; and the company’s plans for further expansion in the U.S. is scheduled for Wednesday, July 29, at 11:00 a.m. ET. Interested parties may access the conference remotely by dialing (719) 457-6209 and entering passcode 243908.

About Marker Test Diagnostics

Founded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative urine marker for the drug testing market. Marker Test Diagnostics has completed research studies in the field of addiction and sports, and has collaborated and published scientific papers with the Olympic Doping Laboratory at the University of California Los Angeles, and the Columbia University / New York State Psychiatric Institute.

For more information about Marker Test Diagnostics, visit www.markertest.com.

About PSO Laboratory

PSO Laboratory provides precision toxicology testing for physicians, practices and health care organizations. PSO Laboratory uses only the most advanced and reliable testing methods utilizing Liquid Chromographic/Mass Spectrometry (LC/MS) technology. PSO Laboratory’s team has extensive experience in testing for prescription and illicit substance abuse.

PSO Laboratory has exceptional support for its physicians and practices. For more information about PSO Laboratory, visit

PSO Laboratory, LLC to Enhance Patient Care by Providing Drug Testing Marker in Michigan
July 28, 2015 08:00 AM Eastern Daylight Time

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Marker Test Diagnostics, Inc., a leading international supplier to the drug testing industry, has secured its second agreement to distribute its UR Code™ urine marker product in the U.S. with PSO Laboratory, a leading provider of drug confirmation testing and toxicology services in Michigan.

“We are very proud to partner with PSO labs as an exclusive sole source distribution partner for the state of Michigan”

UR Code is a urine marker that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection. In the form of a soft gel capsule, UR Code is the only patented test worldwide that can analytically detect sample substitution, dilution or adulteration, resulting in unparalleled accuracy and reliability. This superior level of accuracy eliminates up to 30% of the tests that are deliberately falsified in urine drug testing.

The agreement provides PSO Labs with an exclusive and distinct competitive advantage to improve confirmation in all drug testing market segments in the state of Michigan and a non-exclusive in all other U.S. markets. The companies plan to commercialize the product before the end of the summer.

“We are very proud to partner with PSO labs as an exclusive sole source distribution partner for the state of Michigan,” said Marker Test Chief Executive Officer Kim Christensen. “We believe that together, we can improve the drug testing process in all market segments in Michigan with the focused efforts of PSO Labs. This exclusive three-year agreement gives PSO the opportunity to expand their confirmation statewide. We believe PSO has the expertise and operational excellence to rapidly expand and distribute UR Code as we work together to find ways to reduce the costs of drug testing overall.”

“Marker Test’s unique patient identification system fits perfectly with PSO Laboratory’s focus on patient care, precision toxicology testing and patient responsibility,” stated Michael Barna, M.D., Director of Laboratory Services for PSO Labs. “With the assurance that the sample is correctly associated with the patient, a physician’s ability to provide the patient with an accurate diagnosis and treatment plan is greatly increased. In addition, the often embarrassing and time consuming process of having a staff member monitor the patient during sample collection is eliminated. PSO is excited by this opportunity to provide better patient care by offering the Marker Test program.”

Representatives from Marker Test will be on-site during the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting July 26–30 at the Georgia World Congress Center in Atlanta, Ga (booth 4918). A press conference to discuss the UR Code product; Marker Test’s recent partnerships with PSO and Elithea Sciences; and the company’s plans for further expansion in the U.S. is scheduled for Wednesday, July 29, at 11:00 a.m. ET. Interested parties may access the conference remotely by dialing (719) 457-6209 and entering passcode 243908.

About Marker Test Diagnostics

Founded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative urine marker for the drug testing market. Marker Test Diagnostics has completed research studies in the field of addiction and sports, and has collaborated and published scientific papers with the Olympic Doping Laboratory at the University of California Los Angeles, and the Columbia University / New York State Psychiatric Institute.

For more information about Marker Test Diagnostics, visit www.markertest.com.

About PSO Laboratory

PSO Laboratory provides precision toxicology testing for physicians, practices and health care organizations. PSO Laboratory uses only the most advanced and reliable testing methods utilizing Liquid Chromographic/Mass Spectrometry (LC/MS) technology. PSO Laboratory’s team has extensive experience in testing for prescription and illicit substance abuse.

PSO Laboratory has exceptional support for its physicians and practices. For more information about PSO Laboratory, visit www.psolab.com.

Contacts

Marker Test Diagnostics
Angela Brown, 703-585-4914
pr@markertest.com.

Contacts

Marker Test Diagnostics
Angela Brown, 703-585-4914
pr@markertest.com

07.24.2015 | Marker Test Diagnostics Enters Into Exclusive Agreement to
Distribute UR Code™ Product

Elithea Sciences to Provide Drug Testing Marker for Chronic Pain Management Markets in Texas and Florida

SCOTTSDALE - July 22, 2015 – Marker Test Diagnostics, Inc., a leading international supplier to the drug testing industry, has secured its first agreement to distribute its UR Code urine marker product in the U.S. with Elithea Sciences, a leading provider of drug confirmation testing, toxicology and analytical services.

UR Code is a urine marker that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection. In the form of a soft gel capsule, UR Code is the only patented test worldwide that can analytically detect sample substitution, dilution or adulteration, resulting in unparalleled accuracy and reliability. This superior level of accuracy eliminates up to 30% of the tests that are deliberately falsified in urine drug testing.

The agreement provides Elithea Sciences with a distinct competitive advantage to improve confirmation testing results to physicians and clinics in chronic pain management markets Florida and Texas. In addition, Elithea has the right of first refusal from Marker Test for six additional states: Georgia, Kentucky, Louisiana, Mississippi, Tennessee and West Virginia. The companies plan to commercialize the product before the end of the summer.

“We believe partnering with Elithea Sciences will be the first step in changing the culture of the drug testing industry in the United States,” said Marker Test Chief Executive Officer Kim Christensen. “Together, we have listened to important segments of the industry and recognize that eliminating the observed urine collection process is a major accomplishment in improving the overall integrity and quality of the urine sample, while returning dignity and respect to the sample donor. Elithea Sciences now has an exclusive tool to eliminate the false negative urine known as the ‘substituted sample.’”

“Marker Test’s break-through innovation in drug testing is the perfect complement to Elithea’s subscription recurring revenue-based business model and specialized focus on chronic pain management,” stated Mac Brown, Chief Executive Officer of Elithea Sciences. “Through this partnership with Marker Test, Elithea is offering an investment opportunity in the only solution in the urine drug testing market that virtually assures 100% accuracy and reliability in sample collection, resulting in dramatically-improved patient care.”

Representatives from Marker Test will be on-site during the 2015 American Association for Clinical Chemistry (AACC) Annual Meeting July 26–30 at the Georgia World Congress Center in Atlanta, Ga (booth 4918). A press conference to discuss the UR Code product, Marker Test’s partnership with Elithea Sciences and the company’s plans for further expansion in the U.S. is scheduled for Wednesday, July 29, at 11:00 a.m. ET. Interested parties may access the conference remotely by dialing (719) 457-6209 and entering passcode 243908.

About Marker Test Diagnostics
Founded in 2013, Marker Test Diagnostics is the producer of UR Code (TM), an innovative urine marker for the drug testing market. Marker Test Diagnostics has completed research studies in the field of addiction and sports, and has collaborated and published scientific papers with the Olympic Doping Laboratory at the University of California Los Angeles, and the Columbia University / New York State Psychiatric Institute.

For more information about Marker Test Diagnostics, visit www.markertest.com.

About Elithea Sciences
Elithea Sciences is a leading provider of drug confirmation testing, toxicology and analytical services. We offer specialized range of customizable solutions for accurate, reliable and cost effective testing with a specific focus on prescription medication management, illicit substance identification and performance enhancing drug detection using only the most advanced LC-MS/MS technology available today.

Elithea provides a safe, effective and discreet solution for drug testing analysis that virtually assures 100% accuracy and reliability in obtained sample integrity.

For more information about Elithea Sciences, visit www.elithea.care.

Media Contact:
Angela Brown
pr@markertest.com
703.585.4914

10.31.2014 | Marker Test Diagnostics Announces Date for UR Code™ Product Launch
CEO to Present on Innovation in Drug Testing During Industry Conference in San Diego

Marker Test Diagnostics, an international supplier to the drug testing industry, announced today that the company will begin a comprehensive launch for its revolutionary drug testing marker UR Code™ on November 3. Previously available exclusively in Europe, UR Code is an oral marker developed by Marker Test that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection.

In advance of the launch, Marker Test Chief Executive Officer Kim Christensen will present during the California Consortium of Addiction Programs and Professionals Annual Conference in San Diego, California on November 1. Christensen’s topic will be, “Shifting the Paradigm: Implementing a urine-based marker in the U.S. drug testing market.” The presentation is based on a white paper published last summer by Christensen describing the urgency for change in the drug testing industry.

Christensen recently discussed UR Code’s U.S. market expansion during the Society of Forensic Toxicology (S.O.F.T.) Conference in Grand Rapids, Michigan, and the California Association of Drug and Alcohol Counselors (C.A.A.D.A.C.) Conference in San Diego, California.

07.13.2015 | Marker Test Diagnostics Announces Relocation of U.S. Headquarters

Marker Test Diagnostics, Inc., a leading international supplier to the drug testing industry, announced today that the company has completed a corporate relocation for its U.S. headquarters from Leesburg, Va. to Chandler, Az.

The move will centralize critical business functions and key members of the company’s senior management team, creating operational efficiencies for Marker Test and its partners as it continues to penetrate the U.S. market.

“As we continued our expansion in the U.S., there was a clear need to consolidate the company’s operations in a single geographic region that would be easily accessible to the company’s leadership team,” stated Marker Test Chief Executive Officer Kim Christensen.

In addition to Christensen, the relocation creates an operational hub for the company’s General Counsel; Chief Financial Officer; Controller and Marketing, warehouse and distribution functions in Arizona.

"We believe these efforts will bring stability, efficiency and significant cost savings to our operations and allow our leadership team to operate in a much more streamlined manner,” noted Christensen.

Official U.S. Headquarters:
Marker Test Diagnostics, Inc.
5891 West Orchid Lane
Chandler, AZ 85226
480.598.5162
www.markertest.com
email: info@markertest.com

Mailing Address:
Marker Test Diagnostics, Inc.
9393 N. 90th Street
Suite #102 #502
Scottsdale, AZ 85258

09.25.2014 | Marker Test Diagnostics Announces US Release of Game-Changing Drug Testing Marker

Marker Test Diagnostics, an international supplier to the drug testing industry, announced today that UR Code™, its revolutionary drug testing marker is now available in the United States. Once only available in Europe, UR Code is an oral marker developed by Marker Test that “bar-codes” a subject’s urine and eliminates the need to supervise urine collection.

The U.S. launch for UR Code arrives on the heels of an exhaustive RFI and RFP process used to identify U.S.-based partners for marketing and selling the UR Code product in the United States.

“Interest generated by that process has led to open discussions with several major laboratories and manufacturers that have a high degree if interest obtaining exclusive market or national distribution rights to the UR Code product,” said Kim Christensen, Chief Executive Office of Marker Test. “We are very excited about the success we’ve already achieved with UR Code’s entry into the U.S. market.”

In the form of a soft gel capsule, UR Code provides an accurate, secure and cost-effective answer to common drug testing challenges by:
• Inhibiting manipulations
• Eliminating false negative results
• Ensuring sample integrity
• Protecting the privacy of the test subject

Last summer, Christensen published “Paradigm Shift: A Blueprint for Value Recognition and Process Improvement in the U.S. Drug Testing Market,” a white paper describing the urgency for change in the drug testing industry.

Christensen will discuss UR Code’s U.S. market expansion during the Society of Forensic Toxicology (S.O.F.T.) Conference October 21-24 in Grand Rapids, Michigan, and the California Association of Drug and Alcohol Counselors (C.A.A.D.A.C.) Conference October 28-Nov 1, 2014 in San Diego, California.

08.05.2014 | Marker Test Diagnostics Formally Launches Request for Proposals (RFP) to Support US Expansion

On August 5, 2014, Marker Test Diagnostics distributed a Request for Proposals (RFP) to a short list of top-tier laboratories. The RFP will allow the laboratories to compete for consideration for exclusivity to market and sell the UR Code ™ product in the market segment(s) awarded by Marker Test. Proposals are due August 30, 2014.

For more information regarding the release of the RFP and Marker Test Diagnostics’ US expansion strategy, contact info@markertest.com.

07.18.2014 | Marker Test Diagnostics to Showcase Groundbreaking Drug Testing Marker During AACC Conference

Marker Test Diagnostics’ CEO Kim Christensen, Chairman of the Board Donal Quinn and President Caroline Bussenius will be on-site during the 2014 American Association for Clinical Chemistry (AACC) Annual Meeting in Chicago to discuss the company’s groundbreaking drug testing product, UR Code. Scheduled for July 27 – 31, the AACC annual conference is the world’s largest gathering for laboratory medicine, with exhibitors and attendees representing global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and more. To learn more about the meeting, click here.

06.20.2014 | Marker Test Diagnostics Releases Request for Information to Support Entry into US Drug Testing Market

Marker Test Diagnostics has announced the upcoming release of a Request for Information (RFI) to support its expansion into the US drug testing market. The RFI will enable Marker Test to evaluate potential laboratory partners that best align with the company’s plans to accelerate adoption of its UR Code product in the US.

The RFI is the third step in a five-step process to introduce UR Code in the US, and establish a product distribution strategy that will allow laboratories to leverage their strength in gaining market share and provide incremental revenue streams in preferred markets.

For more information regarding the RFI, contact info@markertest.com.

03.01.2014 | Marker Test Diagnostics Announces New Chief Executive Officer

Marker Test Diagnostics announces its appointment of Kim Christensen as Chief Executive Officer.

Previously, Mr. Christensen was the Director at Syva, the Drug Testing Diagnostics division at Siemens Diagnostics Healthcare. He has extensive knowledge of the American drug testing market, new product introduction and strategic planning.

Mr. Christensen holds a Master of Arts in Organizational Management from the University of Phoenix.

10.24.2013 | New Website Launch

Marker Test Diagnostics invites visitors to explore its new website that went live on October 24, 2013.

The website provides user-friendly navigation and quick, easy access to essential information about Marker Test Diagnostics and its products. The News & Events sections will keep visitors informed about the latest developments and commercial launch of the product.

09.25.2013 | Pilot Batch Manufacturing

Marker Test Diagnostics proudly announces two pilot batches of the UR Code gels commenced production in the United States in mid-September. Our Florida partner is manufacturing these batches under cGMP conditions and they anticipate completing the project in early November.

The soft gels produced during this first cycle are intended for use in clinical studies and patient trials.

02.01.2013 | Marker Test Diagnostics Announces New President

Marker Test Diagnostics announces its appointment of Caroline Bussenius as President of Marker Test Diagnostics.

Previously, Ms. Bussenius served in various marketing and sales positions at Ruma GmbH, Marker Test Diagnostics’ sister company in Germany.

She has extensive knowledge and understanding of the UR Code product, new product introduction and marketing strategy. Ms. Bussenius holds a Bachelor of Science degree in International Business from the Cologne University of Applied Sciences.